October 26th 2024
FDA accepts rivoceranib/camrelizumab NDA for review in HCC, acalabrutinib triplet yields responses in untreated mantle cell lymphoma, and more from OncLive this week.
October 15th 2024
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
PER LIVER CANCER TUMOR BOARD: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable ...
November 16, 2024
Register Now!
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Practice Connections™: Optimize the Diagnosis and Treatment of HER2-Positive Colorectal Cancer
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease
View More
Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition
December 6, 2024
Register Now!
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
22nd Annual Winter Lung Cancer Conference®
January 31, 2025 - February 2, 2025
Register Now!
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting
View More
BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD
View More
(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
EU Panel Recommends Pembrolizumab/Chemo Combo in Squamous NSCLC
February 4th 2019The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for first-line treatment with pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel in patients with metastatic squamous non–small cell lung cancer.
EU Panel Backs Frontline Atezolizumab Regimen in NSCLC
February 2nd 2019The European Medicine’s Agency Committee for Medicinal Products for Human Use has recommended approval for the frontline combination of atezolizumab, bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic, nonsquamous non–small cell lung cancer.
FDA Expands Pemetrexed Approval for Frontline Pembrolizumab/Chemo Combo in NSCLC
January 31st 2019The FDA has expanded the indication for pemetrexed in combination with pembrolizumab and platinum-based chemotherapy for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer without EGFR or ALK alterations.
Brahmer Provides a Glimpse of Future Immunotherapeutics in NSCLC
Despite the rapidly expanding therapeutic options available in immunotherapy for patients with non-small cell lung cancer, there are still a number of drawbacks to treatment, explaining why not all patients respond to current treatment options.
Dr. Brahmer on Managing Immune-Related AEs in Lung Cancer
January 26th 2019Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses managing immune-related adverse events in lung cancer.
Dr. Garon on Potential for Immunotherapy in EGFR+ NSCLC
January 26th 2019Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the potential for immunotherapy in the treatment of patients with EGFR-positive non–small cell lung cancer.
BMS Withdraws Application for Nivolumab/Ipilimumab in TMB-High NSCLC
January 24th 2019Bristol-Myers Squibb has withdrawn its supplemental biologics license application for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the frontline treatment of patients with advanced non–small cell lung cancer with tumor mutational burden ≥10 mutations per megabase.
Dr. Choueiri Discusses Immunotherapy in RCC
January 23rd 2019Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses immunotherapy in the treatment of patients with renal cell carcinoma.
Immunotherapy/Chemo Combinations Show Continued Benefit in NSCLC
January 17th 2019Several clinical trials have evaluated the addition of immunotherapy to standard chemotherapy in the frontline treatment of patients with advanced non–small cell lung cancer, all of which echo similar conclusions: these combinations are a mainstay in this population.
Controversy Adds Caution to CRISPR Editing in United States
January 17th 2019The development of cancer treatments and diagnostic tools using CRISPR/Cas9 and other gene-editing technology is a promising area of research in the United States, although the field is moving into human studies at a relatively slow pace.
FDA Accepts sBLA for Frontline Atezolizumab Plus Carboplatin/Nab-Paclitaxel in Nonsquamous NSCLC
January 17th 2019The FDA has accepted a supplemental biologics license application for atezolizumab, carboplatin, and nab-paclitaxel as a first-line treatment for patients with metastatic nonsquamous non–small cell lung cancer.
Dr. Subramanian on Ongoing Trials for Patients With Nonsquamous NSCLC
January 16th 2019Janakiraman Subramanian, MD, medical oncologist, director of Thoracic Oncology, Center for Precision Medicine, Saint Luke’s Cancer Institute, discusses ongoing trials evaluating the use of immunotherapy in patients with nonsquamous non–small cell lung cancer (NSCLC).
Dr. Wright Discusses Immunotherapy in Bladder Cancer
January 15th 2019Jonathan L. Wright, MD, MS, FACS, medical director, Urology Clinic, University of Washington Medical Center, affiliate investigator, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, discusses immunotherapy in bladder cancer.
Dr. Figlin on Considerations for Combining TKIs and Immunotherapy in RCC
January 10th 2019Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses considerations when combining TKIs and immunotherapy agents in the management of advanced renal cell carcinoma.
Dr. Perez-Soler on Immunotherapy Advances in SCLC
January 7th 2019Roman Perez-Soler, MD, chairman of the Department of Oncology and chief of the Division of Medical Oncology at Montefiore Medical Center, discusses recent advances in immunotherapy for the treatment of patients with small cell lung cancer.
Dr. Bellmunt Highlights Immunotherapy Options in Bladder Cancer
January 4th 2019Joaquim Bellmunt, MD, PhD, genitourinary oncologist, Beth Israel Deaconess Medical Center, associate professor of medicine, Harvard Medical School, differentiates between immunotherapy options available for the treatment of patients with in bladder cancer.